Live Breaking News & Updates on Riptide Bioscience

Stay updated with breaking news from Riptide bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases

Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of . ....

United States , United Kingdom , Neil Solomons , Rob Huizinga , Glenn Schulman , Peter Greenleaf , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Drug Administration , Riptide Bioscience Inc , Thunderbolt Pharma Inc , Investor Relations Corporate Communications , Chief Executive Officer , Recombinant Fc Protein Targeting , Thunderbolt Pharma , B Cell Activating Factor , Proliferation Inducing Ligand , United State Food , Chief Medical Officer , Riptide Bioscience , Executive Vice President , British Columbia , Annual Report , Canadian Securities Administrator System , Electronic Document Analysis , Exchange Commission ,